Aequus Pharmaceuticals (TSE:AQS) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aequus Pharmaceuticals has secured an exclusive deal with Advanced Ophthalmic Innovations to distribute the PAUL® glaucoma drainage device in Canada, a product already approved in over 40 countries. The agreement enhances Aequus’s ophthalmology portfolio and leverages its existing sales infrastructure, aiming for a Canadian launch in Q4. The PAUL® device offers an innovative treatment option for patients with moderate to severe glaucoma, aligning with Aequus’s commitment to improving eyecare.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.